Midlothian, VA and Wayne, NJ –January 24, 2013 – Patient Services, Inc. (PSI) and Bayer HealthCare are pleased to announce the Kogenate® FS Co-pay/Co-Insurance Assistance Pilot Program. The pilot program is funded by Bayer to help qualified Kogenate® FS patients with their out-of-pocket payments.
What is offered through the pilot program?
PSI will administer and determine eligibility for the Program to help Kogenate® FS patients afford their copay/coinsurance expenses.
Patients are qualified to apply for the pilot program* if:
- They have Hemophilia A.
- They meet specific financial criteria for enrollment.
- They currently have private health insurance
- Who is not eligible for assistance?
- Patients on public health insurance are not eligible for assistance at this time. This includes but is not limited
- to patients insured through Medicare, Medicaid, TriCare, DOD plans, PCIP programs, and High Risk Plans associated with a PCIP.
- Patients enrolled in Bayer Assistance Programs.
- Once approved for assistance:
- Financial assistance may be provided for up to 12 months or as long as funding is available. Funds administered by PSI can only be used towards a patient’s co-pay/co-insurance expenses for Bayer’s Kogenate® FS.
- Financial assistance will be based on each patient’s specific health plan design and annual income, subject to yearly and per payment maximums.
As a condition of payment, patients and pharmacies must comply with all contractual obligations made with Third-Party Payers and insurance companies, and must provide notice of any benefits received and the value of this program to all payers as required by law, contract, or otherwise.
“We are proud to be launching our Co-pay/Co-insurance Assistance Pilot Program in partnership with PSI,” said Leslie Donato, Vice President and General Manager, Hematology, Bayer HealthCare Pharmaceuticals. “It is an example of our long-standing commitment to helping patients with hemophilia.”
For inquiries regarding the Kogenate® FS Co-pay/Co-Insurance Assistance Pilot Program, please contact Bayer’s Factor Solutions at 1-800-288-8374. Please remember that applications will be processed and patients will be enrolled on a first-come, first-served basis. Program may be cancelled or changed at any time without notice.
INDICATIONS AND USAGE
Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.
IMPORTANT SAFETY INFORMATION
The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF.
The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.
Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.
For important risk and use information, please see the full prescribing information.
About Patient Services, Inc.
Patient Services Inc. (PSI) (www.patientservicesinc.org) is a “ground breaking” 501(c)(3) non-profit, charitable organization. Founded in 1989 by Dana Kuhn, Ph.D., the Midlothian, Virginia based company has helped people who live with specific chronic illnesses or conditions locate suitable health insurance coverage and access ways to satisfy expensive co-payments. PSI provides assistance with the cost of health insurance premiums associated with COBRAs, State High Risk Pools, Open enrollment, Guaranteed Issue policies, HIPAA conversion policies, PCIPs (Pre-existing Condition Insurance Plans); and prescriptions co-payments associated with private insurance as well as with Medicare Parts B and D.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG.
One of the world’s leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals is comprised of the following business units: Women’s Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology and Oncology. Our aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
Kogenate® FS, Bayer® and the Bayer Cross® are registered trademarks of Bayer.